Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.

Together these investigations on T and B cell subsets suggest that cladribine treatment impairs the B-T cell crosstalk and reduces their ability to mediate pathogenic effector functions. This may result in specific reduction of autoreactivity to RASGRP2 which is expressed in B cells and brain tissue. This article is protected by copyright. All rights reserved.